Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

Publication date: Available online 28 January 2020Source: Urology Case ReportsAuthor(s): Shinro Hata, Satoki AbeAbstractIn the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related adverse events (irAEs). However, the occurrence of hematological irAEs is rare. Some studies have reported on nivolumab-induced thrombocytopenia. Nivolumab associated thrombocytopenia in almost all patients improved with administration of various drugs. However, there have been only a few cases that have reported death owing to cancer aggravation. In this paper, we have described a case of nivolumab-induced thrombocytopenia after third-line treatment for metastatic RCC.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research